Article
Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels.
Kidney international - 1 Nov 2003
Kimura Hideki, Miyazaki Ryoichi, Imura Toshio, Masunaga Shinya, Suzuki Satoru, Gejyo Fumitake, Yoshida Haruyoshi
Abstract excerpt
BACKGROUND: Uremic dyslipidemia characterized by reduced high-density lipoprotein (HDL) cholesterol levels is one of the major contributors to the high incidence of cardiovascular disease in hemodialysis patients. Hepatic lipase (HL), together with cholesteryl ester transfer protein (CETP), may not only promote reverse cholesterol transport but also enhance production of small, dense, more atherogenic low-density...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.